The global market for upstream bioprocessing equipment was worth US$ 7.75 billion in 2022 and is predicted to increase at a CAGR of 12.90% between 2022 and 2032. By 2032, the market is expected to be worth US$ 26.08 billion.
| Attributes | Details |
|---|---|
| Upstream Bioprocessing Equipment Market CAGR | 12.9% |
| Upstream Bioprocessing Equipment Market Size 2022 | US$ 7.75 billion |
| Upstream Bioprocessing Equipment Market Size 2032 | US$ 26.08 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As the prevalence and incidences of chronic diseases have increased, so has the need for more medications to cure them. It is possible to provide high-quality biologic medications and higher productivity with technological innovation, equipment, and a well-established production system. This boosts the market for upstream bioprocessing equipment by increasing its adoption.
Along with the increased demand for cell therapy research, the market drivers for major upstream bioprocessing equipment are drug discovery, antibody synthesis, monoclonal antibody manufacturing, and recombinant production.
The high cost of establishing an upstream processing unit, its upkeep since the present goal is to eliminate contamination, and the area necessary for the setup are important impediments to market’s expansion.
The global market for upstream bioprocessing equipment is expanding. The United States and Europe have been the strongest regions for the growth of upstream process equipment, with double-digit growth over the previous year. When compared to continuous upstream bioprocessing equipment, single-use bioprocessing units have developed dramatically in the United States.
Along with Europe and the United States, emerging economies such as Asia-Pacific, the Middle East, and Africa have significant potential for the growth of upstream bioprocessing equipment. The Japanese beverage, food, and pharmaceutical industries are diversifying into high-value products, which have bolstered Japanese market growth. The Japanese government also offers financial support for research and development to market players of upstream bioprocessing equipment for expansion, allowing the industry to thrive.
To keep up with the market competitiveness and increase their revenue share, key firms engage in a variety of activities. The top players in the market are GE Healthcare, Merck KGaA, Boehringer Ingelheim Pharma GmbH & Co.KG, Thermo Fisher Scientific, BiOZEEN and Katalyst Bio Engineering
Principal Consultant
In September 2028, Thermo Fisher signed an agreement with Becton, Dickinson and Company to buy its advanced bioprocessing business, which includes cell culture media, feed, and supplements to support the upstream biopharmaceutical manufacturing process. This acquisition bolstered Thermo Fisher's bio-production offering in the bioprocessing industry.
In 2019, Jefferson announced the development of the Jefferson Institute for Bioprocessing to educate and train students in professional biological manufacturing, which is expected to stimulate industry growth. Jefferson also established collaboration with the National Institute for Bioprocessing Research and Training to promote initiatives among young people
Bioprocessing referred as biopharmaceutical manufacturing, is a part of bioprocess engineering which aims at establishing reproducible and robust manufacturing process for the production of therapeutic cells. The products of bioprocess are of high commercial value and targeted application.
Bioprocess Manufacturing is differentiated into two major processes: Upstream and Downstream. The Upstream process involves steps such as media development, cell culture, and development, harvesting of cells and fermentation. This process is done under the stringent aseptic condition, and particular temperature and pH levels are maintained throughout the process. Cell Banking is also done by upstream processes.
The primary objective upstream processes are to provide an environment necessary for the growth of cells. Since the upstream process is a part of bio manufacturing process, it involves the production of therapeutic proteins, antibiotics, hormones, enzymes, blood substitutes, and vaccines. Many of the diseases like lymphoma, rheumatoid arthritis, diabetes mellitus and growth hormone insufficiency that can be treated by specific proteins produced from bioprocesses. There are two types of cells used in the bioprocessing equipment, mammalian cells, and bacterial cells.
As the prevalence and incidence of chronic diseases have increased, there is a need to increase the production of substances to cure them. With innovation in technology, equipment with the well-established production system, providing high-quality biologic drugs and increased productivity is possible. This, in turn, increases the usage of upstream processing equipment which drives the biopharmaceutical market.
Along with this increase in the need for cell therapy research, drug discovery, antibody production, monoclonal antibody and recombinant productions are also the major drivers for the upstream bioprocessing equipment market. However, the high cost incurred in setting up an upstream processing unit, its maintenance as the current challenge is to eliminate the contamination and the space required for the setup are the major restraining factors for the growth the Upstream Bioprocessing Equipment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The upstream bioprocessing equipment market can be segmented according to the type of cell used, type of processing, by product, by end users, and by geography. By type of cell, the upstream bioprocessing equipment is segmented as mammalian cell and bacterial cell. According to the processing, the market is segmented into disposable, single - use bioprocessing system and continuous bioprocessing systems.
By type of product the bioreactors and fermenters. By end users, the upstream bioprocessing equipment market is segmented into biopharmaceutical manufacturing companies and research organizations. Geographical segmentation is North America, West Europe, APEJ, Japan, Eastern Europe, Latin America and the Middle East and Africa.
The Single-use bioprocessing units are the major drivers in the coming decade as single-use bioprocessing units eliminated the risk of contamination. It also reduces the time required for the sterilization between batch which in turn also increases the efficacy.
Over a decade disposable and single - use processing units have gained momentum as it is possible to develop a small amount of drugs used for pre - clinical and clinical testing. The future in the upstream bioprocessing system is single - bioprocessing units as it has all kinds of the system used in upstream processing such as bioreactors, membrane absorbers, bioprocess containers, disposable mixers, and samplers.
Geographically the market for bioprocessing equipment is increasing globally. The U.S. and Europe been the strong regions for the growth of upstream processes equipment has it has shown double-digit growth over last year. In U.S. the Single-use bioprocessing units have grown significantly when compared to continuous bioprocessing system.
Along with Europe and U.S., the emerging markets like Asia Pacific and the Middle East and Africa shows great potential for the growth of upstream bioprocessing equipment market. Japanese beverage, food and pharmaceutical industry are diversifying into high-value products which boosted the growth of upstream bioprocessing equipment in Japan. The government in Japan also provides financial support for research and development to industry players for the growth, which enables the industry to prosper.
The top players in the Upstream Bioprocessing Equipment market are GE Healthcare, Merck KGaA, Boehringer Ingelheim Pharma GmbH & Co.KG, Thermo Fisher Scientific, BiOZEEN and Katalyst Bio Engineering
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The market is likely to register a CAGR of 12.9% through 2032.
The market is currently valued at US$ 7.75 Bn in 2022.
The market is likely to grow to a valuation of US$ 26.08 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Healthcare Insights
View Reports
Upstream Bioprocessing Equipment Market
